Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2023/09/06/2738464/36946/en/Orbus-Therapeutics-Announces-First-Patient-Enrolled-in-Phase-1-Clinical-Study-in-Newly-Diagnosed-Glioblastoma.html
https://www.globenewswire.com/news-release/2023/01/10/2586093/36946/en/Orbus-Therapeutics-Enters-Exclusive-License-Agreement-for-Intellectual-Property-Related-to-Treatment-of-Rare-Pediatric-Syndrome-with-Eflornithine.html
https://www.globenewswire.com/news-release/2022/01/19/2369409/36946/en/Orbus-Therapeutics-Phase-3-Eflornithine-STELLAR-Study-Reaches-Full-Patient-Enrollment.html
https://www.globenewswire.com/news-release/2021/09/28/2304662/36946/en/Orbus-Therapeutics-Granted-European-Patent-for-Method-of-Use-for-Eflornithine.html
https://www.globenewswire.com/fr/news-release/2021/03/02/2185498/0/en/Orbus-Therapeutics-Announces-Positive-Outcome-of-Pre-Planned-Interim-Futility-Analysis-for-Phase-3-Eflornithine-STELLAR-Study.html
https://www.globenewswire.com/news-release/2020/12/23/2150089/0/en/Orbus-Therapeutics-Receives-U-S-Patent-for-Eflornithine-Formulations.html#:~:text=PALO%20ALTO%2C%20Calif.%2C%20Dec,entitled%20%E2%80%9CFormulations%20for%20Administration%20of
https://www.globenewswire.com/news-release/2020/12/23/2150089/0/en/Orbus-Therapeutics-Receives-U-S-Patent-for-Eflornithine-Formulations.html#:~:text=PALO%20ALTO%2C%20Calif.%2C%20Dec,entitled%20%E2%80%9CFormulations%20for%20Administration%20of